Charles Schwab Investment Management Inc. Boosts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Charles Schwab Investment Management Inc. grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,184,609 shares of the biopharmaceutical company’s stock after buying an additional 7,939 shares during the period. Charles Schwab Investment Management Inc.’s holdings in TG Therapeutics were worth $27,708,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. NBC Securities Inc. raised its holdings in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares during the last quarter. Quarry LP increased its stake in shares of TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 503 shares during the period. Private Advisor Group LLC increased its stake in shares of TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 542 shares during the period. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the period. Finally, KBC Group NV increased its stake in shares of TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,092 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Up 1.5 %

TGTX stock opened at $33.88 on Thursday. The firm has a market cap of $5.27 billion, a PE ratio of -337.50 and a beta of 2.25. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm’s fifty day moving average is $27.03 and its 200 day moving average is $22.56. TG Therapeutics, Inc. has a one year low of $12.84 and a one year high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 earnings per share. On average, research analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. HC Wainwright increased their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. The Goldman Sachs Group increased their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. B. Riley increased their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. raised their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.